Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
Trump Administration Approves Nvidia H200 AI Chip Sales to China Under New Export Rules 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
Alphabet Stock Poised for Growth as Bank of America Sees Strong AI Momentum Into 2026 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
AFT Leaves X Over AI-Generated Images of Minors 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
U.S. Government Invests $1 Billion in L3Harris Rocket Motor Business to Secure Missile Supply Chain 
LA JOLLA, Calif., March 29, 2017 -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines, today announced that results from preclinical studies of tipifarnib, KO-947, its development candidate targeting ERK1/2 kinases, and KO-539, its development candidate targeting the menin-MLL interaction, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2017. The AACR Annual Meeting will be held at the Walter E. Washington Convention Center in Washington, D.C. from April 1-5, 2017.
The following posters will be presented during the conference. Abstracts are available at www.aacr.org.
Apr. 3, 2017, 1:00 p.m. - 5:00 p.m. EDT – Abstract 2063/20 (Poster): The farnesyltransferase inhibitor tipifarnib causes dramatic tumor regression and increases survival in murine HrasG12V driven aggressive thyroid cancers: Consequent adaptive and acquired resistance mechanisms inform combination treatments with improved responses. B. Untch et al., Memorial Sloan Kettering Cancer Center, New York, NY
Apr. 5, 2017, 8:00 a.m. - 12:00 p.m. EDT – Abstract 5168/11 (Poster): KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors. F. Burrows et al., Kura Oncology, La Jolla, Calif.
Apr. 5, 2017, 8:00 a.m. - 12:00 p.m. EDT – Abstract 5077/22 (Poster): A novel small molecule menin-MLL inhibitor for potential treatment of MLL-rearranged leukemias. T. Wu et al., Wellspring Biosciences, La Jolla, Calif.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials. The pipeline includes KO-947, an ERK inhibitor, and KO-539, an inhibitor of the menin-MLL protein-protein interactions. For additional information about Kura Oncology, please visit the company’s website at www.kuraoncology.com.
Forward Looking Statements
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the potential utility of Kura Oncology’s drug candidates, the conduct, results and timing of preclinical studies and clinical trials and plans regarding future research and development. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "promise, " "potential," "expects," "plans," "anticipates," "intends," "continues," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to the Company's periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Kura Oncology assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT INFORMATION INVESTOR CONTACT: Robert H. Uhl Managing Director Westwicke Partners, LLC (858) 356-5932 [email protected] MEDIA CONTACT: Mark Corbae Vice President Canale Communications (619) 849-5375 [email protected]
